UHPLC

NEW YORK (GenomeWeb News) – Advion today said that its expression compact mass spectrometer has been integrated with liquid chromatography systems from Agilent Technologies.

Several mass spec vendors presented this week at the UBS Global Life Sciences Conference in New York City, offering information on various aspects of their businesses, including portions of their proteomics portfolios.

With the deal, Bruker becomes the latest company to acquire an LC business to complement its mass spec instruments.

With executives from Agilent, Thermo Fisher, Waters, and Danaher presenting this week at the JP Morgan Healthcare Conference, UPLC as well as triple quadrupole and qual-quan mass spec proved primary areas of discussion.

The release of a long-awaited protein biomarker test, increased adoption of a major instrument platform, and a pair of proteome mapping milestones marked a year in which several much-anticipated advances in proteomics arrived.

The purchase, which is expected to close in the first quarter of 2011, will add a range of ion and liquid chromatography products to Thermo Fisher's portfolio, including platforms aimed at proteomics research like Dionex's UltiMate 3000 RSLCnano LC system.

The company's Life Sciences Group reported $431 million in revenues, with all platforms posting double-digit sales increases including a 21-percent rise in liquid chromatography sales led by the strong performance of the 1290 and 1260 Infinity LC lines.

CEO Frank Whitney noted that HPLC sales were particularly strong in the Asia-Pacific market, and that the company had seen increased demand from its life science customers compared to the first quarter of 2010.

In a third quarter earnings call, CEO Douglas Berthiaume said growing demand for the Acuity H-Class UPLC platform helped drive a 9-percent rise in instrument sales year over year, while total receipts increased 9 percent and profit widened 25 percent.

CEO Bill Sullivan cited the 1290 Infinity LC and the recently introduced 1260 Infinity and 1220 Infinity platforms as drivers of the company's liquid chromatography business.

Pages

The US Food and Drug Administration has new guidelines that enable some gene and cell therapies to undergo expedited review, according to the New York Times.

Using gene drives to control invasive species might be too risky, an initial advocate of the approach says.

Researchers have grown tumors in 3D cell cultures to better understand cancer, the Economist reports.

In Science this week: intellectual property experts argue patent battles such as the one over CRISPR are wasteful, and more.